Precision BioSciences公司宣布，其针对杜氏肌营养不良症（DMD）的首创基因疗法Pbgene-Dmd，已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）申请批准。这一重要监管里程碑为该疗法进入临床研究阶段铺平了道路。
Precision BioSciences公司宣布，其针对杜氏肌营养不良症（DMD）的首创基因疗法Pbgene-Dmd，已获得美国食品药品监督管理局（FDA）的新药临床试验（IND）申请批准。这一重要监管里程碑为该疗法进入临床研究阶段铺平了道路。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.